Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study

European Journal of Surgical Oncology

Volumn 37, Issue 10, 2011, Pages 856-863

  Semiglazov, V ^a   Eiermann, W ^b   Zambetti, M ^c   Manikhas, A ^d   Bozhok, A ^a   Lluch, A ^e   Tjulandin, S ^f   Sabadell, M D ^g   Caballero, A ^e   Valagussa, P ^h   Baselga, J ^g   Gianni, L ^c  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b Frauenklinik vom Roten Kreuz   (Germany)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d City Oncological Hospital   (Russian Federation)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h Fondazione Michelangelo   (Italy)

Author keywords

Conservative surgery; Locally advanced breast cancer; Neoadjuvant chemotherapy; Pathological complete remission; pCR; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATORY BREAST CANCER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052967755     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.07.003     Document Type: Article

References (31)

1. K.W. Hance, W.F. Anderson, S.S. Devesa, H.A. Young, and P.H. Levine Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 13 2005 966 975 (Pubitemid 41430562)
2. M. Sant, C. Allemani, and F. Berrino European Concerted Action on survival and care of cancer patients (EUROCARE) Working group. Breast carcinoma survival in Europe and the United States Cancer 100 4 2004 715 722
3. National Comprehensive Cancer Network (NCCN) Clinical Guidelines in Oncology Breast Cancer, Version 2 2010 http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf
4. S. Dawood, S.D. Merajver, and P. Viens International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment Ann Oncol Jul 5, 2010 http://annonc.oxfordjournals.org/content/early/ 2010/07/03/annonc.mdq345.long [Epub ahead of print], doi:10.1093
5. S. Chia, S.M. Swain, D.R. Byrd, and D.A. Mankoff Locally advanced and inflammatory breast cancer J Clin Oncol 26 5 2008 786 790 (Pubitemid 351264392)
6. B. Brun, Y. Otmezguine, and F. Feuilhade Treatment of inflammatory breast cancer with combination chemotherapy and mastectomy versus breast conservation Cancer 61 6 1988 1096 1103 (Pubitemid 18078597)
7. J.N. Fields, C.A. Perez, and R.R. Kuske Inflammatory carcinoma of the breast: treatment results on 107 patients Int J Radiat Oncol Biol Phys 17 2 1989 249 255 (Pubitemid 19203069)
8. M. Panades, I.A. Olivotto, and C.H. Speers Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis J Clin Oncol 23 9 2005 1941 1950 (Pubitemid 46211373)
9. I.J. Bristol, W.A. Woodward, and E.A. Strom Locoregional treatment outcomes after multimodality management of inflammatory breast cancer Int J Radiat Oncol Biol Phys 72 2 2008 474 484
10. C.A. Perez, J.N. Fields, and P.M. Fracasso Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma Cancer 74 1 Suppl 1994 466 476 (Pubitemid 24187665)
11. R.Y. Fleming, L. Asmar, and A.U. Buzdar Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma Ann Surg Oncol 4 6 1997 452 461 (Pubitemid 127725217)
12. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
13. M. Marty, F. Cognetti, and D. Maraninchi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 2005 4265 4274 (Pubitemid 46207001)
14. I. Smith, M. Procter, R.D. Gelber for the HERA study team Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
15. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
16. D. Slamon, W. Eiermann, and N. Robert Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study Breast Cancer Res Treat 94 Suppl. 1 2005 S5
17. M.A. Cobleigh, C.L. Vogel, and D. Tripathy Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648 (Pubitemid 29415219)
18. J. Baselga, X. Carbonell, and N.J. Castañeda-Soto Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Clin Oncol 23 2005 2162 2171 (Pubitemid 46218708)
19. H.J. Burstein, L.N. Harris, and P.K. Marcom Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2003 2889 2895 (Pubitemid 46621838)
20. A.M. Wardley, X. Pivot, and F. Morales-Vasquez Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer J Clin Oncol 28 6 2010 976 983
21. B. Kaufman, J.R. Mackey, and M.R. Clemens Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study J Clin Oncol 27 2009 5529 5537
22. S. Dawood, A.M. Gonzalez-Angulo, and F. Peintinger Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience Cancer 110 6 2007 1195 1200 15 (Pubitemid 47435588)
23. R.S. Mehta, T. Schubbert, and K. Kong Trastuzumab in inflammatory breast cancer Ann Oncol 19 10 2008 1815 1817
24. S. Dawood, Y. Gong, and K. Broglio Trastuzumab in primary inflammatory breast cancer (IBC): high pathological response rates and improved outcome Breast J 16 5 2010 529 532
25. B. Kaufman, M. Trudeau, and A. Awada Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study Lancet Oncol 10 6 2009 581 588
26. H. Boussen, M. Cristofanilli, T. Zaks, M. DeSilvio, V. Salazar, and N. Spector Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer J Clin Oncol 28 20 2010 3248 3255
27. L. Gianni, W. Eiermann, and V. Semiglazov Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: a randomized phase III trial with a parallel HER2-negative cohort (the NOAH trial) Lancet 375 2010 377 384
28. S. Dawood, U. Broglio, Sha -Wan-Kan, and G. Hortobaqyi Prognostic value of initial clinical disease stage after achieving pathological complete response The Oncologist 13 1 2008 6 15 (Pubitemid 351206692)
29. B. Fisher, J. Bryant, and N. Wolmak Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672 2685 (Pubitemid 28363030)
30. H.M. Kuerer, L.A. Newman, and T.L. Smith Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 1999 460 469 (Pubitemid 29075229)
31. F. Thomas, R. Arriagada, and M. Spielmann Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy Cancer 76 11 1995 2286 2290